ArticleOncology letters2026
Predictive value analysis of CEA, CA125 and CYFRA21-1 levels in evaluating the efficacy of tislelizumab combined with gemcitabine-cisplatin chemotherapy in patients with advanced non-small cell lung cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While chemoimmunotherapy is the standard for advanced non-small cell lung cancer (NSCLC), effective and accessible tools for monitoring early treatment response are needed. The present study evaluated the clinical efficacy and safety of tislelizumab + gemcitabine-cisplatin (GP) chemotherapy vs. GP alone in NSCLC, and assessed serum CEA, CA125 and cytokeratin 19 fragment (CYFRA21-1) levels for treatment monitoring. In total, 90 patients with advanced NSCLC (from January 2021 to December 2024) were randomized in a 1:1 manner to receive tislelizumab + GP (n=45) or GP chemotherapy alone (n=45). Outcomes included short-term response [objective response rate (ORR) and disease control rate (DCR)], long-term progression-free survival (PFS) and overall survival (OS) (data cut-off, May 31, 2025; median follow-up, 23.5 months), 3-month biomarker changes and adverse events (AEs). The tislelizumab + GP group demonstrated numerically higher ORR/DCR (P>0.05), significantly longer median PFS (20.8 vs. 10.0 months, P=0.03) and a trend toward improved OS (not reached vs. 16.0 months; P=0.095). Post-treatment biomarker levels were significantly decreased in the study group (P<0.05) with comparable AEs. Receiver operating characteristic curves analyzed the diagnostic value of the combined biomarker panel compared with each biomarker individually for the prediction of short-term efficacy, which demonstrated significantly enhanced performance for the combination (P<0.05). In conclusion, combined CEA, CA125 and CYFRA21-1 effectively evaluated short-term efficacy. Furthermore, tislelizumab + GP demonstrated favorable safety and improved survival outcomes (particularly PFS) within follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.